immunotherapy | pharmaphorum

Skip to main content

Sunday 20 September 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

immunotherapy

News

AstraZeneca Amenities Building - Mississauga - Sept 2005
Non exclusive, unlimited time license for print & web to WZMH Architects

AZ sells US/Canada rights for old breast cancer drug

AstraZeneca has sold US and Canadian rights to its older breast cancer drug Zoladex to TerSera Therapeutics in a deal worth up to $320 million.

Partner Content

io360_rgb

Partner Content

Immuno-Oncology: A 360° View in NYC this February

The Conference Forum has announced that the 3rd annual

News

Natural killer cells are a type of lymphocytes which destroy cancer cells and other altered cells releasing cytotoxic granules.

BMS and PsiOxus to collaborate on cancer-targeting armed vir...

BMS to pay up to $936m for NG-348.

News

AZ new HQ 600

AZ stakes its claim in immunotherapy with bladder cancer fil...

After looking like it could get left far behind by rivals in immunotherapy, AstraZeneca has made its first filing for PD-L1 drug durvalumab .

News

Merck-sign

Avelumab filed, Pfizer and Merck prepare to join immunothera...

Checkpoint inhibitor drug set to be fourth competitor in PD-1/PD-L1 market

News

edinburgh

Scotland to fund BMS skin cancer combo

Patient evidence convinces SMC Opdivo+Yervoy is cost-effective.

Load more results

Editor's Picks

NICE finally backs Enhertu for HER2-low breast cancer

Novo Nordisk rebrands as Novo as new CEO charts turnaround

MPs seek probe into UK-US pharma deal's impact on NHS

FDA unveils framework for its expedited IND pilot

WCLC: Lung cancer news from BioNTech, Akeso, and Roche

News

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company